𝔖 Bobbio Scriptorium
✦   LIBER   ✦

422 The mode of action of CYC202 (R-roscovitine) a cyclin dependent kinase inhibitor currently in phase II clinical trials

✍ Scribed by S. Green; D.E. MacCallum; I.N. Fleming; J. Melville; M. Watson; S. Frame; K. Watt; S. Anderson; A. Gianella-Borradori; D.P. Lane

Book ID
118621605
Publisher
Elsevier Science
Year
2004
Tongue
English
Weight
126 KB
Volume
2
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

In vitro and in vivo antitumor propertie
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
✍ Steven J. McClue; David Blake; Rosemary Clarke; Angela Cowan; Lorna Cummings; Pe πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 French βš– 112 KB

## Abstract CDK2 inhibitors have been proposed as effective anti‐cancer therapeutics. We show here that CYC202 (__R__‐roscovitine) is a potent inhibitor of recombinant CDK2/cyclin E kinase activity (IC~50~ = 0.10 ΞΌM) with an average cytotoxic IC~50~ of 15.2 ΞΌM in a panel of 19 human tumour cell lin